Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$6.06 - $7.64 $2.43 Million - $3.06 Million
-400,434 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$5.06 - $6.36 $750,423 - $943,219
148,305 Added 58.82%
400,434 $2.25 Million
Q3 2017

Nov 14, 2017

BUY
$5.71 - $6.9 $1.44 Million - $1.74 Million
252,129
252,129 $1.58 Million

Others Institutions Holding AUPH

About Aurinia Pharmaceuticals Inc.


  • Ticker AUPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,892,000
  • Market Cap $1.02B
  • Description
  • Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...
More about AUPH
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.